(Q39904967)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Biological markers in inflammatory bowel disease: practical consideration for clinicians (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

inflammatory bowel diseases

17 January 2020

main subject

0 references

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

J L Mendoza

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

1 June 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

Gastroenterologie Clinique et Biologique

17 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

33 Suppl 3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

S158-73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestiv

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Laboratory markers in IBD: useful, magic, or unnecessary toys?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A simple method for assessing intestinal inflammation in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serologic markers in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Biomarkers and surrogate endpoints: preferred definitions and conceptual framework

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Biomarkers of cardiovascular disease: molecular basis and practical considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Acute-phase proteins and other systemic responses to inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serum C-reactive protein levels in disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Laboratory Markers of Colonoscopic Activity in Ulcerative Colitis and Crohn's Colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

C-reactive protein as a marker for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Clinically active Crohn's disease in the presence of a low C-reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

The role of C-reactive protein in the resolution of bacterial infection

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Monocyte-conditioned medium, interleukin-1, and tumor necrosis factor stimulate the acute phase response in human hepatoma cells in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Why measure C reactive protein?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

The mystique of the erythrocyte sedimentation rate. A reappraisal of one of the oldest laboratory tests still in use.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Tests for detecting and monitoring the acute phase response

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A Comparison Between Erythrocyte Sedimentation Rate (ESR) and Selected Acute-Phase Proteins in the Elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Platelets and inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Persistence of hemostatic alterations in patients affected by Crohn's disease after bowel surgery

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Mean platelet volume: a useful marker of inflammatory bowel disease activity

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Thromboembolism in inflammatory bowel disease: role of platelets

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Non-invasive investigation of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Enzymes in feces: useful markers of chronic inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Review article: faecal markers in the assessment of activity in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

111Indium autologous granulocytes in the detection of inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

High prevalence of NSAID enteropathy as shown by a simple faecal test

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal calprotectin levels in healthy children studied with an improved assay

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Faecal calprotectin: a marker of inflammation throughout the intestinal tract

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal S100A12: a novel noninvasive marker in children with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Lactoferrin: a multifunctional glycoprotein involved in the modulation of the inflammatory process

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal lactoferrin: a new parameter to monitor infliximab therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Detection of pro- and anti-inflammatory cytokines in stools of patients with inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Faecal elastase reflects disease activity in active ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal tumor necrosis factor-alpha and calprotectin as differential diagnostic markers for severe diarrhea of small infants

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Controversies in IBD. Serologic tests are helpful in managing inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

IBD serological panels: facts and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Utility of serological markers in inflammatory bowel diseases: gadget or magic?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Advances in clinical laboratory tests for inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serological markers in inflammatory bowel diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A prospective comparative study of ASCA and pANCA in Chinese and Caucasian IBD patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Anti-Saccharomyces cerevisiae antibodies in Japanese patients with inflammatory bowel disease: diagnostic accuracy and clinical value

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Identification of a novel bacterial sequence associated with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Association of antibodies to exocrine pancreas with subtypes of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Pancreatic Autoantibodies in Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Bacterial flagellin is a dominant antigen in Crohn disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Use of serologic markers as a screening tool in inflammatory bowel disease compared with elevated erythrocyte sedimentation rate and anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

C-reactive protein as an aid in the differentiation of functional and inflammatory bowel disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Fecal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serologies in Crohn's disease: can we change the gray zone to black and white?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Relevance of serologic studies in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Role of serology and routine laboratory tests in childhood inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Anti-outer membrane of porin C and anti-I2 antibodies in indeterminate colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

The value of serologic markers in indeterminate colitis: a prospective follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Is antibody testing for inflammatory bowel disease clinically useful?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A simple biological score for predicting low risk of short-term relapse in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

The clinical significance of serum C reactive protein levels in Crohn's disease. Results of a prospective longitudinal study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Variants of CARD15 are Associated with an Aggressive Clinical Course of Crohn's Disease-An IG-IBD Study

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in caucasian Crohn's disease patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Role of ASCA and the NOD2/CARD15 mutation Gly908Arg in predicting increased surgical costs in Crohnʼs disease patients: A project of the European Collaborative Study Group on Inflammatory Bowel Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Biomarkers in inflammatory bowel disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Natalizumab for active Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

C-reactive protein: anti-placebo or predictor of response

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Faecal calprotectin: a marker of inflammation throughout the intestinal tract.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Predictors of early response to infliximab in patients with ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Seroreactivity to microbial components in Crohn's disease is associated with ileal involvement, noninflammatory disease behavior and NOD2/CARD15 genotype, but not with risk for surgery in a Hungarian cohort of IBD patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Phases of biomarker development for early detection of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Biomarkers for neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Discovery of biomarker candidates within disease by protein profiling: principles and concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Genome-wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: lessons for study design

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Lack of common NOD2 variants in Japanese patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

The future of genetic studies of complex human diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Deskription der medizinischen Versorgung von jüngeren Patienten (<65 Jahre) mit kolorektalem Karzinom in Schleswig-Holstein und Abgleich der Bereiche Diagnostik und Therapie mit der aktuellen S3-Leitlinie

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Genetic analysis of host resistance: Toll-like receptor signaling and immunity at large

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

Maximizing the potential of functional genomics

1 reference

https://api.crossref.org/works/10.1016%2FS0399-8320%2809%2973151-3

7 January 2021

10.1016/S0399-8320(09)73151-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20117339%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference